

47. An expression vector according to claim 46, wherein said amino acid sequence is IGF-I. *NO A.B.*

48. An expression vector according to claim 46, wherein said polypeptide is IGF-I. *NO A.B.*

REMARKS

In conformance with MPEP §1453 regarding amendments of reissue claims, applicants have made amendments as follows: Patent claims 1-3 and 6-18 were amended by underscored insertions and bracketed deletions. Claims 23-28 and 31-35, not being original patent claims, were amended by cancelation of the claims presented in the reissue application and submitting amended claims entirely underscored without indication of additions or deletions. Claims 42-48 are newly added. New claims 42 and 43 are similar to claims 25 and 26. Each will be explained hereinafter; new claims 44-48 are directed to vectors not previously claimed.

The Examiner's rejections of claims 1, 6-9 and 14-41 in paragraphs 5 and 6 are well taken since the sequences (c) and (d) cover complementary sequences or fragments which do not encode "IGF". As now amended claims 1, 8 and 18 are directed to a "nucleic acid molecule" comprising a nucleic acid sequence selected from the group: (a), (b), (c) and (d). Their dependent claims have also been amended appropriately. Applicants believe that the incorrect identifications have been eliminated and that the presently claimed subject matter is described and enabled by the specification. Reconsideration is respectfully requested in view of this

amendment.

The Examiner's rejection of claims 23, 24 and 31 has also been overcome by the appropriate identification of nucleic acid sequences (a) and (b) in claims 1, 8 and 18 and their dependent claims. Reconsideration is respectfully requested in view of this amendment.

The Examiner's rejection of claims 27 and 28 as indefinite is acknowledged and those claims have been corrected by rewriting said claims using essentially the format suggested by the Examiner. Again, reconsideration is respectfully requested in view of this amendment.

New claims 44-47 are directed to vectors added as the result of a discussion with the Examiner concerning vectors. It is understood that the addition of such claims at this point will not be objectionable.


In compliance with 37 CFR §1.178, applicants enclose the original patent herewith. In the event that this reissue application is not allowed, it is understood that the original patent shall be returned to applicants.

In compliance with 37 CFR §1.175(a)(2) applicants are in the process of having a Supplemental Reissue Declaration signed by each of the three inventors that covers errors being corrected in the reissue application "up to the time of filing" the reissue application, and with 37 CFR §1.175(b)(1) covering additional errors not covered by §1.175(a)(2). An unsigned copy of said declaration is enclosed so that the Examiner can see the format at this time.

It appears that all grounds of rejection have been satisfied and the application is

now in condition for allowance. Please call the undersigned attorney if there are any outstanding issues or questions.

Respectfully submitted,



Francis A. Paintin

Attorney for Applicants

Registration No. 19,386

Date: Jan. 27, 2000

WOODCOCK WASHBURN KURTZ

MACKIEWICZ & NORRIS LLP

One Liberty Place - 46th Floor

Philadelphia, PA 19103

Tel. (215) 568-3100

Fax. (215) 568-3439